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Abstract
Background: the term frailty refers to a condition of increased vulnerability to stressors among older people, leading to a
decline in homeostatic reserve. Frailty often leads to falls, hospitalisation and mortality, hence its importance for the delivery of
health care to older adults. The pathophysiological mechanisms behind frailty are not well understood, but the decreased
steroid-hormone production and elevated chronic systemic inﬂammation of older people appear to be major contributors.
Method: we used a sample of 3,160 individuals aged 50 or older from the English Longitudinal Study of Ageing and assessed
their frailty status according to a Frailty Index. We selected 620 single nucleotide polymorphisms in genes involved in the
steroid hormone or inﬂammatory pathways. We performed linear association analysis. The outcome variable was the square
root transformation of the Frailty Index, with age and sex entered as covariates.
Results: the strongest signal was detected in the pro-inﬂammatory Interleukin-18 gene (rs360722, P = 0.0021, β= −0.015).
Further signiﬁcant signals were observed in the Interleukin-12 (rs4679868, P= 0.0062, β =−0.008 and rs9852519,
P = 0.0077, β = −0.008), low density lipoprotein receptor-related protein 1 (rs1799986, P = 0.0065, β= 0.011) and Selectin-P
(rs6131, P= 0.0097, β= −0.01) genes. None of these associations remain signiﬁcant after Bonferroni correction.
Conclusions: we show potential associations between genetic variants of four genes and the frailty index. These genes are
involved in the cholesterol transport and inﬂammatory pathway and, as such, our results provide further support for the in-
volvement of the immunological processes in frailty of the elderly.
Keywords: genetics, SNP, Frailty Index, inflammation, older people
Introduction
While it is accepted that the core feature of frailty is increased
vulnerability to stressors due to impairments in multiple, inter-
related systems that lead to decline in homeostatic reserve and
resilience [1], the pathophysiological pathways behind this con-
dition are not well understood.
Performance-based measures of frailty, such as the frailty
phenotype [2] have found associations between decreased
sex hormone levels such as testosterone, dehydroepiandros-
terone (DHEA) and its sulphate derivative (DHEAS) and
frailty [3, 4]. The levels of these hormones gradually decline
with age, around 1–3%/year [5, 6]. The role that these
hormones play in body mass [7, 8], muscle strength [9, 10]
and bone mineral density [11, 12] gives biological support to
the relation between these sex hormone levels and the per-
formance-based measures of frailty.
Moreover, these hormones have an effect on inﬂammatory
cytokines. Testosterone exerts a suppressive effect on pro-
inﬂammatory cytokines, such as Interleukin-1β (IL-1β) and
tumor necrosis factor (TNF) and increases anti-inﬂammatory
cytokine Interleukin-10 (IL-10) [13], whereas DHEA seems to
have an effect on Interleukin-6 (IL-6) levels [14].
In line with these results, age-related increases in cyto-
kines and their association with performance measured
frailty have been described in the literature [15, 16].
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These results indicate a possible frailty mechanism, where
the decreasing sex hormone and increasing inﬂammatory cyto-
kine production during ageing yields a chronic low-level inﬂam-
matory state, which is responsible for the frailty symptoms.
Another robust and ﬂexible measure of frailty is based on
the concept of deﬁcit accumulation quantiﬁed as a Frailty
Index (FI) [17]. Deﬁcits can be symptoms, or functional
impairments that accumulate with age, such as problems car-
rying out daily activities, or chronic illnesses. Although this
measure has received less attention in association studies, the
FI was shown to be associated with lower levels of total and
free testosterone and DHEAS in men [18] and increased
levels of biomarkers of inﬂammation: basal IL-6, basal TNF
and C-reactive protein [19].
The aim of this study was to conduct a candidate gene
association study using the FI as a phenotypic measure in
3,160 community-dwelling individuals over the age of 50 in
the English Longitudinal Study of Ageing (ELSA) panel study.
We selected genes involved in the steroid hormone bio-
synthesis and inﬂammation pathways, as evidence in the lit-
erature indicates their possible involvement in frailty
pathophysiology (for example DHEAS [18], IL-6, TNF and
C-reactive protein [19]). We hypothesised that single nucleo-
tide polymorphisms (SNPs) within these genes, especially
those ones which have been shown to affect the expression
of their genes such as rs1800795 for IL6 [20] and rs1800629
for TNF [21] will show signiﬁcant association to FI.
Methods
Participants
The analyses are performed on a sample of 3,160 partici-
pants drawn from Wave 2 (2004) of the ELSA. Detailed de-
scription of ELSA can be found elsewhere ([22] www.
elsa-project.ac.uk/, 14 September 2015, date last accessed).
Brieﬂy ELSA is a prospective panel study representative of
community-dwelling men and women over 50 living in
England. The participants have answered a computer assisted
personal interview biannually collecting a wide range of infor-
mation on social, psychological, functional and health
domains. All participants provided signed consent and ethical
approval was granted by the London Multi-Centre Research
Ethics Committee.
Genetic data
Genotype data of 620 SNPs for 3,160 participants were
obtained from the publicly available ELSA DNA Repository
(EDNAR).
Genotyping was performed by Illumina (San Diego, CA,
USA) as part of a 1,536 Goldengate custom SNP panel
using high-throughput BeadArrayTM technology.
Phenotypic measures
An ELSA Frailty Index (FI) was created following guidance
in the literature [17] using Wave 2 data. Brieﬂy, the FI counts
health-related problems (deﬁcits) in a range of domains
(activities of daily living, cognitive function, falls and fractures,
joint replacement, vision, hearing, chronic diseases, cardio-
vascular diseases, depression). Only individuals with non-
missing values for at least 30 of the 62 frailty components
were included. A full list of the components is available in
Appendix 1 (Supplementary data in Age and Ageing online).
The FI had a negatively skewed distribution so we performed
square root transformation.
Statistical analysis
We used the Plink software for genetic association analyses
[23]. Associations between genotypes and square root trans-
formed FI were tested with linear regression using sex and age
as covariates. Stata12 software (Stata Corporation, http://
www.stata.com/, 14 September 2015, date last accessed)
was used for the demographic and phenotypic analysis.
Genetic power calculation was performed by Quanto software
(http://biostats.usc.edu/software, 14 September 2015, date
last accessed).
Results
Demographic and phenotypic results
Table 1 shows the demographic and phenotypic results.
There were more females than males in the sample with no
signiﬁcant differences between the mean ages. The mean FI
score was signiﬁcantly higher in women than in men (two
sample t-test, P < 0.0001).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1.Demographic and phenotypic results
Total sample Males Females
Number of participants 3,160 1,466 1,694
Mean age years (SE) in Wave 2 68.3 (0.10) 68.27 (0.14) 68.32 (0.14)
Mean FI scores (SE) in Wave 2 0.153 (0.0018) 0.140 (0.0025) 0.164 (0.0025)
SE, standard error; FI, Frailty Index.
Figure 1. Frailty Index distribution in Wave 2 before square
root transformation. FI, Frailty Index.
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The distribution of the 62 item FI was skewed towards
lower scores; therefore we performed square root transform-
ation to normalise the distribution before the genetic associ-
ation analysis (Figure 1). The lowest untransformed score
was 0, the highest 0.634. As expected, age was positively
associated with the FI which was lowest in the youngest
group (age 60–64, mean FI = 0.133, SE = 0.003) and increased
in the consecutive age groups (age 65–69, mean FI = 0.144,
SE = 0.003, age 70–74, mean FI = 0.166, SE = 0.004, age
75–79, mean FI = 0.185, SE = 0.004).
Genetic association analysis results
Of the received 620 SNPs, 15 were out of Hardy–Weinberg
equilibrium (P < 0.01), and a further 15 had a minor allele
frequency (MAF) below 5%, so these were excluded from
the genetic association analysis, resulting in 590 SNPs used.
The full list of 590 SNPs can be found in Appendix 2
(Supplementary data, available in Age and Ageing online).
The most signiﬁcant results of the genetic association
analysis can be seen in Table 2. One SNP reached sig-
niﬁcance level below P = 0.005, rs360722 (IL18), which
decreased the FI (β = −0.015, uncorrected P-value =0.0021).
Four SNPs were below the P= 0.01 threshold, rs4679868
(IL12A) (β=−0.008, uncorrected P-value = 0.0062), rs9852519
(IL12A) (β=−0.008, uncorrected P-value = 0.0077) and rs6131
(SELP) (β= −0.01, uncorrected P-value =0.0097), all de-
creasing the FI, whilst rs1799986 (LRP1) (β= 0.011, uncor-
rected P-value =0.0065) increased the FI. A further 12 SNPs
were below the P= 0.05 signiﬁcance level (see Supplementary
data, Appendix 2, available in Age and Ageing online).
Several of these SNPs were in high linkage disequilibrium
(rs4679868 and rs9852519, r2 = 0.92, rs2886666 and rs747825,
r2 = 0.97 (all IL12A), rs6131 and rs3917729, r2 = 0.65, both
SELP); therefore the number of independent signals is fewer.
None of these results survives the Bonferroni correction
(P < 8.474E-05).
Discussion
Our candidate gene association study is the ﬁrst to investigate
the association between the Frailty Index and genes involved
in steroid hormone metabolism and inﬂammatory pathways.
Of the ﬁve top hits, inﬂammatory pathways are represented
by four SNPs that are located in three genes, IL18, IL12 and
SELP. IL-18 is a powerful pro-inﬂammatory cytokine which
plays a pivotal role in systemic and local inﬂammation,
whereas IL12 is a major cytokine produced by antigen present-
ing cells and represents the link between the cellular and
humoral branches of an effective host immune defence [24].
The third gene SELP encodes a cell adhesion molecule with a
role in inﬂammation and haemostasis. During the former, it
takes part in the tethering, rolling and weak adhesion of leuko-
cytes, whereas in haemostasis it stabilises platelet aggregates
and determines the size of aggregates [25].
IL-18 levels increase with age, similarly to IL-6 and CRP
levels [26]. To our knowledge, IL-18 levels have not been
investigated in relation to frailty, but higher IL-18 levels have
been signiﬁcantly associated with poorer physical perform-
ance (including balance, walk test and chair rise test) and
with difﬁculties performing six activities of daily living
(including bathing, dressing, eating, grooming, toileting and
continence) [27]. Physical activity was also reported to be sig-
niﬁcantly and negatively associated with serum IL-18 levels
in Japanese men [28]. The rs360722 A allele appeared to be
protective against rheumatoid arthritis in another Japanese
study [29]. This allele appeared to be protective in our study
too, as it was associated with a decrease in the FI.
There is little information in the literature about the func-
tion of the other SNPs that we identiﬁed as potentially
important. Rs4679868 A and rs9852519T alleles (both in
IL-12A) have been associated with increased risk of primary
biliary cirrhosis [30] whereas the A allele of rs6131 (SELP)
has been found to lower platelet activation upon release of
the cross-clamp in patients undergoing coronary artery
bypass graft [31].
Naturally, these gene-products are all part of the very
complex immune system and they are in interaction with
several other molecules. For example, both IL18 and IL12
stimulate the interferon-γ production (IFN-γ) of Th1 cells,
with a synergistic effect between them [24]. Moreover,
rs360722 A allele (IL18) itself has been associated with a dose-
dependent decrease in the secretion of the pro-inﬂammatory
cytokine tumor necrosis factor (TNF) following smallpox
vaccination [32].
It appears that SELP also has an effect on TNF.
Adhesion of monocytes to SELP increased the secretion of
TNF by the leukocytes when they were stimulated with
platelet-activating factor in vitro [33].
Despite this, none of the eight SNPs in the IFNG and
TNF gene regions showed an association with FI in our
study. Other important inﬂammatory pathway genes, such as
CRP or IL6 (and its receptor IL6R), were also not associated
with the FI, although CRP and IL6 levels have been asso-
ciated with this phenotype [19]. One possible explanation for
this is that IL-18 and IL-12 exert their effect on frailty inde-
pendently from each other, not via increasing the IFN-γ or
TNF levels, perhaps via pathways not related to IL6 or CRP.
The inﬂammatory pathways consist of many members with
complex interactions between them and it is not possible to
evaluate these interactions fully within a candidate gene study
of a limited number of genes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Most significant results of genetic association
analysis
SNP Minor allele MAF β P-value Gene
rs360722 A 0.10 −0.015 0.0021 IL-18
rs4679868 A 0.38 −0.008 0.0062 IL-12A
rs1799986 A 0.15 0.011 0.0065 LRP
rs9852519 A 0.37 −0.008 0.0077 IL-12A
rs6131 A 0.16 −0.01 0.0097 SELP
SNP, small nucleotide polymorphism; MAF, minor allele frequency.
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It is important to note though, that as our results did not
remain signiﬁcant after the Bonferroni-correction; it is pos-
sible that they are false positive associations, although their
agreement is compatible with some previous ﬁndings in the
literature.
We also found a relationship below the P= 0.01 level for
rs1799986, a synonymous variant located within the third
exon of low density lipoprotein receptor-related protein 1
(LRP1) gene on chromosome 12. LRP1 is a large multiligand
receptor involved in several cellular processes, including
intracellular signalling, lipid homeostasis including choles-
terol transport, and clearance of apoptotic cells [34] and
thought to have a role in the pathology of Alzheimer disease
(AD) [34, 35]. Analysis of post-mortem brain tissue showed
that LRP1 levels normally decrease with ageing and were sig-
niﬁcantly lower in the brains of AD patients compared to
controls [35]. There is contradictory evidence in the literature
on the functionality of the rs1799986 polymorphism in AD
[36, 37, 38]. Our results showed that the A allele appeared to
increase the FI which is in agreement with a Spanish study, in
which it was associated with increased risk of premature car-
diovascular disease [39]. On the other hand, as rs1799986 is
a synonymous mutation, it is possible that another SNP
nearby is responsible for the effect. And this result did not
remain statistically signiﬁcant after correction for multiple
testing.
This study has a number of limitations. First, only a pro-
portion of the ELSA sample was genotyped, thus it may not
be as representative as the full sample of the older adults in
England. Secondly, the FI is based on self-reported questions
which may introduce bias into the measure. The distribution
of FI is skewed towards the lower end of the scale; therefore
those with severe frailty are underrepresented in this sample
of community-residing older people. This distribution
however is in line with other reports from the literature.
Thirdly, the genes and genotypic variants were selected from
a publicly available dataset with limited genotyping, rather
than speciﬁcally selected for the purpose of this study.
Finally, we did not have the opportunity to measure serum
IL-18 levels to corroborate our ﬁndings as data on this were
not available in the dataset.
The strengths of our study include the derivation of the
sample from a representative population study of older
adults in England using a panel survey with standardised
interviewer delivered validated protocols. Another important
strength is the achieved sample size. The effective sample
size required to test whether a gene main effect is associated
with a continuous trait for 99% power, α= 0.05 (two-sided
test), assuming outcomes that are modelled using linear re-
gression (mean = 0.153, SD = 0.10, genetic effect = 0.01,
MAF = 0.05) is 1,828, which is given in our study. As with all
genetic association studies it would be advantageous to repli-
cate our ﬁndings.
In summary, our candidate gene association study is the
ﬁrst one to investigate the genetic components of the Frailty
Index and indicates the role of inﬂammation and cholesterol
transport. Although the results are in line with some previous
ﬁndings in the literature, none of the associations remains
statistically signiﬁcant after correction for multiple testing. This
report generates hypotheses and hopefully will encourage
further research into the molecular determinants of frailty in
older adults.
Key points
• Limited evidence exists of plausible biological markers of
frailty.
• To address this we conducted a candidate gene association
study using the Frailty Index in the ELSA.
• The most signiﬁcant signal was within IL-18 gene with
lesser associations in the IL-12, LRP1 and SELP genes.
• Our ﬁndings support that inﬂammatory pathways are
implicated in frailty.
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